Chapter Sixteen

Science, Technology, and Global Health



The Need for New Products

Characteristics of new technologies must reflect the following:

- Most important target groups are poor people
- Quality of care and injection safety is often low
- Many low- and middle-income countries have poorly organized health systems



The Need for New Products

- Diagnostics : specific, sensitive, inexpensive, easy to use, and noninvasive
- Drugs : safe, effective, inexpensive, and able to be used for many years without becoming susceptible to resistance
- Vaccines : safe, effective, inexpensive, include several antigens, and require only one dose to confer lifelong immunity
- Ideally these products would also be easy to transport, heat stable, and not require refrigeration



The Need for New Products

Gaps in current technology:

- Effectiveness of TB vaccine is "limited"
- Drugs for TB, malaria and HIV are susceptible to resistance
- There are no vaccines for HIV, malaria, or any of the NTDs
- HIV drugs can control, but not cure the infection



The Potential of Science and Technology

- Sequencing the genome of pathogens could help improve the development of vaccines and drugs and reduce resistance
- Improvements in technology will facilitate the development of new drugs
- New technologies can assist in the design and manufacture of new vaccines
- Genetic modification of plants could lead to more nutritious and disease resistant crops (but is not always welcome)



Constraints to Applying Science and Technology to Global Health Problems

- For-profit sector does not believe it could make a sufficient profit from products for low-and middle-income countries
- Costs of research and development on new products are very high
- Number of firms engaged in vaccine production is small



Enhancing New Product Development

- Means of reducing the risk of developing new products enough that the forprofit sector might be interested:
- Push Mechanisms : reduce risk and cost of investments
- Pull Mechanisms : assure a future return in the event that a product is produced



Figure 16.1: Some Ideal Characteristics of Diagnostics, Vaccines, Drugs and Delivery Devices

Diagnostics: Affordable; specific and sensitive; provide quick and easy-to-interpret results; easy to store and transport; heat stable

Vaccines: Affordable; safe and effective; require few doses; confers lifelong immunity; easy to transport and store; heat stable

Drugs: Affordable; safe, and effective; not easy for pathogens to become resistant to; require small doses over a limited period; easy to store and transport; heat stable Delivery devices: Affordable, safe, and effective; not invasive; easy to transport and store; heat stable



Product Development Partnerships

- Public-private partnerships created to overcome limitations of the private sector
- Many of these public-private partnerships are product development partnerships (PDPs)
- Examples of PDPs include Aeras, Malaria Vaccine Initiative, International Partnership for Microbicides and the International AIDS Vaccine Initiative

